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Background
In spina bifida aperta (SBA), movements caudal to the
meningomyelocele (MMC) are present in utero, but they
disappear shortly after birth. Insight in onset and progres-
sion of movement loss is therapeutically relevant. Deter-
mination of muscle echogenicity (or density (MD)) is
used to estimate onset and progression of various neu-
romuscular disorders in children. In prenatal SBA, we
hypothesized that MD assessment could indicate onset
and progression of muscle damage in relation to move-
ment loss. Objective: To estimate onset and progression of
muscle changes in fetal SBA by MD assessment.
Materials and methods
MD (muscle/bone pixel-density) was obtained in cali-
brated images (by standardized ultrasound methods). In
SBA (n = 6; GA 22–37 wks) and control fetuses (n = 11;
GA 17–36 wks), we assessed MD in gluteus/gastrocne-
mius (L5-S1), tibialis ant. (L4-5), quadriceps (L2-4), and
biceps/triceps (C5-8) muscles. MMCs were at Th12 (n =
1), L4-5 (n = 1) or L5-S1 (n = 4) level. In SBA fetuses, MD
was compared between muscles from myotomes caudal
and cranial to the MMC. Additionally, MD was compared
between SBA fetuses and aged matched controls (n = 6
and median GA 33 wks in both groups), and between pre-
and postnatal SBA (<1 week after birth). In succumbed
fetuses, MD values were related to histological observa-
tions in affected muscles (3 SBA fetuses).
Results
During MD assessment, movements caudal to the MMC
were present in all SBA fetuses. MD values correlated with
gestational age, both in controls and in SBA myotomes
cranial to the MMC (r = 0.44, p < 0.01; r = 0.50, p < 0.05;
resp.). In contrast, MD values in SBA myotomes caudal to
the MMC did not correlate with gestational age (r = 0.26,
p = 0.13), and were significantly higher than cranial to the
MMC (median +19%, p < 0.01) and controls (+45–60%,
p < 0.01). Longitudinal pre- and postnatal MD values cau-
dal to the MMC did not significantly differ (mean 14%).
MD values in SBA myotomes caudal to the MMC corre-
sponded with histological assessment (extent of atrophic/
hypertrophic muscle fibres).
Conclusion
Despite persisting leg movements in fetal SBA, MD in
myotomes caudal to the MMC is increased prenatally.
Early postnatal disappearance of leg movements is unre-
lated to an additional increase in perinatal MD. Present
data support the concept that permanent movement loss
is related to acute spinal damage rather than to intrinsic
muscle impairment.
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